Additional Effect of Coherent Breathing With Aerobic Exercise on Cardiopulmonary Parameter
This study will use a randomized controlled trial to evaluate the added effects of coherent breathing combined with aerobic exercise versus aerobic exercise alone in 40 adults aged 30-65 with stage 1 hypertension. Participants will be randomly assigned to an intervention group (aerobic exercise plus coherent breathing)
| Condition(s) | Stage 1 Hypertensives |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This study will use a randomized controlled trial to evaluate the added effects of coherent breathing combined with aerobic exercise versus aerobic exercise alone in 40 adults aged 30-65 with stage 1 hypertension. Participants will be randomly assigned to an intervention group (aerobic exercise plus coherent breathing) or a control group (aerobic exercise only) and will undergo a 4-week program with 5 sessions per week. Cardiopulmonary parameters-including blood pressure, heart rate, respiratory rate, and rate pressure product-will be measured, and quality of life will be assessed using the MINICHAL questionnaire at baseline, 2 weeks, and post-intervention. Data will be analyzed using SPSS version 21.0. The study aims to determine whether coherent breathing provides additional benefits, of |
| Who can participate | Inclusion Criteria: * Both male and female genders. * Adults aged 30-65 years. * Patients diagnosed with stage 1 hypertension 130-139/80-89mm Hg according to ACC/AHA 2017 guidelines. * Mild to moderate physical activity level on IPAQ questionnaire. * Individuals able to understand and follow the instructions. Exclusion Criteria: * Diagnosed uncontrolled hypertensive patients. * Unstable angina, MI, heart failure, advanced CAD patients, COPD, Asthma. * Severe neurological, musculoskeletal or gynecological conditions which limit participation in the study. * Recent history of fracture. |
| Ages | 30 Years to 65 Years |
| Sex | All |
| Lead sponsor | Foundation University Islamabad |
| Locations | Islamabad, Pakistan |
| Start date | 2026-02-28 |
| NCT ID | NCT07573683 |
| Official listing | https://clinicaltrials.gov/study/NCT07573683 |